DRTS → $100.00 by May 12, 2027.

Alpha Tau (NASDAQ: DRTS) has announced groundbreaking news. They have achieved complete response in recurring GBM, the most common and aggressive brain cancer. If you listen closely to the conference call, you’ll notice the company is already looking forward, and the FDA is on board. Usually the approval process for biotech companies could take years, but in this case we might be seeing record times to get this life saving treatment to patients. The current standard of care for this …